By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Agendia said today that it has hired Ferrer inCode to distribute its MammaPrint breast cancer diagnostic test in Latin America.

The MammaPrint test is used to identify patients who are at high risk of early metastasis and who are likely to develop metastases within five years after surgery.

Ferrer inCode is a subsidiary of Spain's Grupo Ferrer Internacional that is focused on personalized medicine, genomics, proteomics, and other related technologies.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.